术前超声结合术中淋巴引流导向的乳腺癌精准前哨淋巴结活检

doi:10.6040/j.issn.1671-7554.0.2017.1115

摘要/Abstract

摘要： 目的从术前到术中全程监测前哨淋巴结活检(SLNB),实现精准化治疗并确定其临床应用价值。方法术前超声评估患者腋窝淋巴结状态,定位靠近乳房及异常肿大淋巴结。术中采用亚甲蓝及吲哚菁绿(ICG)双标法显影淋巴管和淋巴结,准确区分真正的前哨淋巴结(trSLN)、前哨旁淋巴结(paSLN)和前哨后淋巴结(poSLN),并仅对trSLN进行切除活检。结果通过评估126例乳腺癌患者,术前超声诊断符合率为78.8%;SLNB特异度、灵敏度、假阴性率(FNR)分别为100%、88.1%、11.9%;多灶性肿瘤假阴性差异有统计学意义(P=0.009),而术前评估淋巴结状态及paSLN是否转移对假阴性的影响差异无统计学意义。结论结合术前超声评估定位,术中淋巴引流导向的SLNB可实现低创伤、低FNR,多灶性肿瘤是假阴性的危险因素。

关键词: 前哨淋巴结, 淋巴引流, 超声, 活检, 乳腺癌

Abstract: Objective Sentinel lymph node biopsy(SLNB)was monitored during the complete surgical procedures to achieve accurate treatment and to determine its clinical value. Methods Axillary lymph nodes were assessed by ultrasound before operation. The lymph nodes near breast which were abnormally enlarged were marked. Intraoperatively, the lymph vessels and nodes were stained with both methylene blue and indocyanine green(ICG). After the true sentinel lymph nodes(trSLNs), para-SLNs(paSLNs)and post-SLNs(poSLNs)were accurately distinguished, the trSLNs were resected for biopsy. Results The evaluation of 126 cases of breast cancer revealed that the coincidence rate of preoperative ultrasound diagnosis was 78.8%. The SLNB specificity, sensitivity, and false negative rate(FNR)were 100%, 88.1% and 11.9%, respectively. The false negative of multifocal tumor was statistically significant(P=0.009), while preoperative assessment of lymph node status and paSLN metastasis were not statistically significant. Conclusion Preoperative ultrasound localization combined with intraoperative drainage guided SLNB can cause few trauma and low false negative rate. Multifocal tumor is a risk factor of false negative.

Key words: Sentinel lymph node, Lymphatic drainage, Ultrasound, Biopsy, Breast cancer

中图分类号:

R615

陈思思,李小燕,江立玉,孔晓丽,马婷婷,杨其峰. 术前超声结合术中淋巴引流导向的乳腺癌精准前哨淋巴结活检[J]. 山东大学学报 (医学版), 2018, 56(1): 50-56.

CHEN Sisi, LI Xiaoyan, JIANG Liyu, KONG Xiaoli, MA Tingting, YANG Qifeng. Precise sentinel lymph node biopsy in breast cancer guided by preoperative ultrasound combined with intraoperative lymphatic drainage[J]. Journal of Shandong University (Health Sciences), 2018, 56(1): 50-56.

参考文献

[1] Krag D, Weaver D, Ashikaga T, et al. The sentinel node in breast cancer-a multicenter validation study[J]. N Engl J Med, 1998, 339(14): 941-946.
[2] Lyman GH, Temin S, Edge SB, et al. Sentinel lymph node biopsy for patients with early-stage breast cancer: American Society of Clinical Oncology clinical practice guideline update[J]. J Clin Oncol, 2014, 32(13): 1365-1383.
[3] Giuliano AE, Hunt KK, Ballman KV, et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial[J]. JAMA, 2011, 305(6): 569-575.
[4] Verbelen H, Gebruers N, Eeckhout FM, et al. Shoulder and arm morbidity in sentinel node-negative breast cancer patients: a systematic review[J]. Breast Cancer Res Treat, 2014, 144(1): 21-31.
[5] Levangie PK, Drouin J. Magnitude of late effects of breast cancer treatments on shoulder function: a systematic review[J]. Breast Cancer Res Treat, 2009, 116(1): 1-15.
[6] El Hage Chehade H, Headon H, Kasem A, et al. Refining the performance of sentinel lymph node biopsy post-neoadjuvant chemotherapy in patients with pathologically proven pre-treatment node-positive breast cancer: an update for clinical practice[J]. Anticancer Res, 2016, 36(4): 1461-1471.
[7] Giuliano AE, Kirgan DM, Guenther JM, et al. Lymphatic mapping and sentinel lymphadenectomy for breast cancer[J]. Ann Surg, 1994, 220(3): 391-398, 398-401.
[8] Fortunato L, Mascaro A, Amini M, et al. Sentinel lymph node biopsy in breast cancer[J]. Surg Oncol Clin N Am, 2008, 17(3): 673-699.
[9] Cox CE, Pendas S, Cox JM, et al. Guidelines for sentinel node biopsy and lymphatic mapping of patients with breast cancer[J]. Ann Surg, 1998, 227(5): 645-651, 651-653.
[10] Layeequr RR, Siegel E, Boneti C, et al. Stage migration with sentinel node biopsy in breast cancer[J]. Am J Surg, 2009, 197(4): 491-496.
[11] Zavagno G, De Salvo GL, Scalco G, et al. A Randomized clinical trial on sentinel lymph node biopsy versus axillary lymph node dissection in breast cancer: results of the Sentinella/GIVOM trial[J]. Ann Surg, 2008, 247(2): 207-213.
[12] Han C, Yang L, Zuo W. A mini-review on factors and countermeasures associated with false-negative sentinel lymph node biopsies in breast cancer[J]. Chin J Cancer Res, 2016, 28(3): 370-376.
[13] Veronesi U, Paganelli G, Viale G, et al. Sentinel lymph node biopsy and axillary dissection in breast cancer: results in a large series[J]. J Natl Cancer Inst, 1999, 91(4): 368-373.
[14] Huang J, Chen X, Fei X, et al. Risk factors of non-sentinel lymph node metastasis and performance of MSKCC nomogramin breast cancer patients with metastatic sentinel lymph node[J]. Zhonghua Wai Ke Za Zhi, 2015, 53(12): 941-946.
[15] Kim B, Verghese ET, Horgan K. Causes of false-negative sentinel node biopsy in patients with breast cancer(Br J Surg 2013; 100: 775-783)[J]. Br J Surg, 2013, 100(10): 1398-1399.
[16] Goyal A, Newcombe RG, Mansel RE, et al. Sentinel lymph node biopsy in patients with multifocal breast cancer[J]. Eur J Surg Oncol, 2004, 30(5): 475-479.
[17] Borgstein PJ, Meijer S, Pijpers RJ, et al. Functional lymphatic anatomy for sentinel node biopsy in breast cancer: echoes from the past and the periareolar blue method[J]. Ann Surg, 2000, 232(1): 81-89.
[18] Buda A, Papadia A, Zapardiel I, et al. From conventional radiotracer Tc-99(m)with blue dye to indocyanine green fluorescence: a comparison of methods towards optimization of sentinel lymph node mapping in early stage cervical cancer for a laparoscopic approach[J]. Ann Surg Oncol, 2016, 23(9): 2959-2965.
[19] Wang M, Zhou W, Zhao Y, et al. A novel finding of sentinel lymphatic channels in early stage breast cancer patients: which may influence detection rate and false-negative rate of sentinel lymph node biopsy[J]. PLoS One,2012,7(12): e51226. doi: 10.1371/journal.pone.0051226.
[20] Suami H, Pan WR, Mann GB, et al. The lymphatic anatomy of the breast and its implications for sentinel lymph node biopsy: a human cadaver study[J]. Ann Surg Oncol, 2008, 15(3): 863-871.
[21] Krag DN, Anderson SJ, Julian TB, et al. Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial[J]. Lancet Oncol, 2007, 8(10): 881-888.
[22] Kuehn T, Bauerfeind I, Fehm T, et al. Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy(SENTINA): a prospective, multicentre cohort study[J]. Lancet Oncol, 2013, 14(7): 609-618.
[23] Kennedy RJ, Kollias J, Gill PG, et al. Removal of two sentinel nodes accurately stages the axilla in breast cancer[J]. Br J Surg, 2003, 90(11): 1349-1353.
[24] Ban EJ, Lee JS, Koo JS, et al. How many sentinel lymph nodes are enough for accurate axillary staging in t1-2 breast cancer?[J]. J Breast Cancer, 2011, 14(4): 296-300.
[25] Yamashita M, Hovanessian-Larsen L, Sener SF. The role of axillary ultrasound in the detection of metastases from primary breast cancers[J]. Am J Surg, 2013, 205(3): 242-244, 244-245.
[26] Tucker NS, Cyr AE, Ademuyiwa FO, et al. Axillary ultrasound accurately excludes clinically significant lymph node disease in patients with early stage breast cancer[J]. Ann Surg, 2016, 264(6): 1098-1102.
[27] Borgstein PJ, Pijpers R, Comans EF, et al. Sentinel lymph node biopsy in breast cancer: guidelines and pitfalls of lymphoscintigraphy and gamma probe detection[J]. J Am Coll Surg, 1998, 186(3): 275-283.
[28] Nakamura R, Yamamoto N, Miyaki T, et al. Impact of sentinel lymph node biopsy by ultrasound-guided core needle biopsy for patients with suspicious node positive breast cancer[J]. Breast Cancer, 2017. doi: 10.1007/s12282-017-0795-7.
[29] Kim WH, Kim HJ, Jung JH, et al. Ultrasound-guided fine-needle aspiration of non-palpable and suspicious axillary lymph nodes with subsequent removal after tattooing: false-negative results and concordance with sentinel lymph nodes[J]. Ultrasound Med Biol, 2017, 43(11): 2576-2581.

相关文章 15

[1]	徐平于国放李霞. 不同类型甲状腺上动脉PSV对Graves病与桥本氏甲状腺炎鉴别诊断的价值[J]. 山东大学学报(医学版), 2209, 47(6): 62-64.
[2]	王艳萍,王玉波,董林,唐娜,徐晴晴,郭广君,郭时金,杨丽梅,徐子贤,张浩天,张文勇,徐倩倩. 响应面优化超声辅助低共熔溶剂提取惠白菊总黄酮工艺[J]. 山东大学学报 (医学版), 2026, 64(5): 29-41.
[3]	齐硕,刘可宇,徐展望,谭国庆,张强. 改良活检优化宏基因组二代测序腰椎间盘感染早期诊断策略[J]. 山东大学学报 (医学版), 2026, 64(2): 96-103.
[4]	古春青,郭睿思,周勤勤,刘恒辉,巴婉玉,孙士玲,王冰,郑玉玲,吴宿慧. 基于网络药理学和动物实验探讨酸枣仁-远志药对治疗乳腺癌相关性失眠的作用机制[J]. 山东大学学报 (医学版), 2026, 64(1): 99-108.
[5]	刘保国,宋翔,赵晓文,毛亚丽. 血清STAT5B、NKAIN1 mRNA检测在乳腺癌中的应用价值[J]. 山东大学学报 (医学版), 2025, 63(7): 68-74.
[6]	王雪梅,杨豪,宋洋,程世超,张婷婷,王艳春. 抗糖尿病药物与女性恶性肿瘤的因果关联:一项两样本孟德尔随机化分析[J]. 山东大学学报 (医学版), 2025, 63(6): 67-77.
[7]	徐梦纯,季翔,陈倩,陈世龙,董亮. 弥漫性肺骨化症1例[J]. 山东大学学报 (医学版), 2025, 63(4): 122-124.
[8]	李懿原,马珊,李爱华,龙飞. 超声支气管镜引导下碘-125粒子植入治疗肺癌中央区淋巴结转移[J]. 山东大学学报 (医学版), 2025, 63(12): 26-34.
[9]	董向毅,刘昕,刘欣欣,徐亚瑄,赵琳丽,陶国伟. 盆腔深部子宫内膜异位症的超声评价[J]. 山东大学学报 (医学版), 2025, 63(10): 34-42.
[10]	余之刚,郑超. 乳腺癌多学科诊疗的现状、挑战与创新模式[J]. 山东大学学报 (医学版), 2025, 63(1): 1-9.
[11]	山东省医学会乳腺疾病多学科联合委员会. 乳腺癌多学科协作诊疗山东共识(2024年版)[J]. 山东大学学报 (医学版), 2025, 63(1): 10-16.
[12]	程跃启,王斐,于理想,郑超,余之刚. 曲妥珠单抗致HER2阳性乳腺癌患者心脏毒性的研究进展[J]. 山东大学学报 (医学版), 2025, 63(1): 17-24.
[13]	王敏, 李习平, 檀军, 邱梅, 侯泽宇, 田莹, 罗鸿莹, 范超文, 齐玲, 俞琦, 谢薇. 慢病毒载体介导Gag-Caspase-8诱导三阴性乳腺癌原代细胞凋亡及S期阻滞[J]. 山东大学学报 (医学版), 2025, 63(1): 25-34.
[14]	张洁,张芳芳,王靖楠,李泽宇,宋颖,李娜. circ_0000144在乳腺癌中的表达及其对乳腺癌细胞增殖、迁移和侵袭能力的影响[J]. 山东大学学报 (医学版), 2025, 63(1): 35-42.
[15]	宋雅雯,郭联涛,孔德光,孙圣荣. VTCN1导致HR+乳腺癌预后不良及内分泌治疗耐药[J]. 山东大学学报 (医学版), 2025, 63(1): 43-59.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed